Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Randomized, Double-blind, Parallel-group Study To Compare The Efficacy Of Golimumab In Combination With Methotrexate (MTX) Versus MTX Monotherapy, In Improving Dactylitis And Enthesitis, In MTX Naïve Psoriatic Arthritis Patients

Next Previous
Search
Trial Profile

A Multicentre, Randomized, Double-blind, Parallel-group Study To Compare The Efficacy Of Golimumab In Combination With Methotrexate (MTX) Versus MTX Monotherapy, In Improving Dactylitis And Enthesitis, In MTX Naïve Psoriatic Arthritis Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary) ; Methotrexate
  • Indications Psoriatic arthritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GO-DACT

Most Recent Events

  • 01 Apr 2020 Results published in the Annals of the Rheumatic Diseases
  • 15 Jun 2019 Due to favorable results on a planned interim analysis recruitment was halted after 44 patients were centrally randomized according to results presented at the 20th Annual Congress of the European League Against Rheumatism
  • 15 Jun 2019 Primary endpoint (Dactylitis Severity Score (DSS)) has been met as per results presented at the 20th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top